JAK1 Genomic Alteration Associated With Exceptional Response to Siltuximab in Cutaneous Castleman Disease.

about

JAK1 Genomic Alteration Associated With Exceptional Response to Siltuximab in Cutaneous Castleman Disease.

Item

http://www.wikidata.org/entity/Q38939643

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

JAK1 Genomic Alteration Associ ...... n Cutaneous Castleman Disease.

@en

type

Item

label

JAK1 Genomic Alteration Associ ...... n Cutaneous Castleman Disease.

@en

prefLabel

JAK1 Genomic Alteration Associ ...... n Cutaneous Castleman Disease.

@en

P1476

JAK1 Genomic Alteration Associ ...... n Cutaneous Castleman Disease.

@en

P2093

Maulik Patel

http://www.w3.org/2001/XMLSchema#string

Sadakatsu Ikeda

http://www.w3.org/2001/XMLSchema#string

Susan R Pilat

http://www.w3.org/2001/XMLSchema#string

P2860

Structural basis for the autoinhibition of focal adhesion kinase

A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.

Transforming JAK1 mutations exhibit differential signalling, FERM domain requirements and growth responses to interferon-γ.

HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy.

Cutaneous castleman's disease responds to anti interleukin-6 treatment.

A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease.

ALL-associated JAK1 mutations confer hypersensitivity to the antiproliferative effect of type I interferon.

The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition.

Structural snapshots of full-length Jak1, a transmembrane gp130/IL-6/IL-6Rα cytokine receptor complex, and the receptor-Jak1 holocomplex.

Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias.

P304

449-452

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.1001/JAMADERMATOL.2016.5554

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

153

http://www.w3.org/2001/XMLSchema#string

P50

Razelle Kurzrock

P577

2017-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28241173

http://www.w3.org/2001/XMLSchema#string

P932

5470416

http://www.w3.org/2001/XMLSchema#string